Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12572 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Ferdinando D'Amico und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Biotherapeutics.
Abstract (Originalsprache)
Background
Crohn's disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by a progressive nature of the disease resulting in subsequent intestinal damage, limited efficacy of current treatments and suboptimal disease management and a significant burden for patients.
Objectives
The IBD‐PODCAST study aims to estimate the proportion of Crohn's disease and UC patients with suboptimal disease control (SDC) in a real‐world setting.
Methods
A non‐interventional and cross‐sectional study was conducted across 103 sites in 10 countries (Austria, Belgium, Canada, Germany, Greece, Italy, Portugal, Spain, Turkey, and UK). Criteria for SDC were based on STRIDE‐II criteria and adapted by an expert panel.
Results
2185 patients (Crohn's disease: n = 1,108, UC: n = 1077) with a mean (SD) age of 44.0 (14.8) years and mean (SD) disease duration of 12.4 (9.2) years were included (52.2% male). Ileal involvement was present in 39.1% of Crohn's disease patients, 35.3% of UC patients had extensive colitis. 77.3% of Crohn's disease and 65.3% of UC patients were on targeted immunomodulators and, according to STRIDE‐II‐based treatment phases, 85.6% of Crohn's disease and 85.4% of UC patients were assigned to the long‐term treatment phase. SDC was detected in 52.2% of Crohn's disease and 44.3% of UC patients predominantly due to impaired quality of life (QoL), clinically significant extraintestinal manifestations, steroid overuse, signs of active inflammation in UC and Crohn's disease, and active fistulas in Crohn's disease. More than one criterion was seen in 37% of patients with SDC. Opportunities for on‐label treatment optimization were observed in 49% of Crohn's disease and 61% of UC patients on advanced therapy.
Conclusion
The high percentage of SDC in this global, real‐world cohort suggests a large disease burden and high unmet medical need in IBD patients. Future analysis should focus on monitoring and responding to SDC in this cohort and on patients' QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Facultad de Medicina, IIS Aragón, Hospital Clínico Universitario "Lozano Blesa", CIBEREHD, Zaragoza, Spain.
- GI-Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, National & Kapodistrian University of Athens, Athens, Greece.
- CINTESIS@RISE Departament, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
- Division of Gastroenterology and Hepatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Claudia Leitner
Förderung
- AbbVie Biotherapeutics
Zitieren
APA
D'Amico, F., Gomollón, F., Bamias, G., Magro, F., Targownik, L., Leitner, C., Heatta-Speicher, T., Michelena, N., Kolterer, S., Lapthorn, J., Kauffman, L., Dignass, A., & IBD PODCAST investigators (2024). Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12572
Vancouver
D'Amico F, Gomollón F, Bamias G, Magro F, Targownik L, Leitner C, et al. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12572
BibTeX
@article{DAmico2024,
author = {D'Amico, Ferdinando and Gomollón, Fernando and Bamias, Giorgos and Magro, Fernando and Targownik, Laura and Leitner, Claudia and Heatta-Speicher, Tobias and Michelena, Naiara and Kolterer, Stefanie and Lapthorn, Jennifer and Kauffman, Laura and Dignass, Axel and IBD PODCAST investigators, IBD PODCAST investigators},
title = {Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12572}
}
EUVIMED